person · Reporting owner
Huizinga Robert Bindert
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | EVP of Research | March 02, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date March 02, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,379 |
Ending reported balance
After 2022-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-02 · Grant · Acquired 8,500 · Balance 74,228 F1: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Row 2 · 2022-03-02 · Sale · Disposed 4,849 · Balance 69,379 F2: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 62,448 |
Reported balance
After 2022-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-02 · Grant · Acquired 62,448 · Balance 62,448 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01 · Expires 2032-03-02 | Direct | 106,838 |
Reported balance
After 2022-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-02 · Grant · Acquired 106,838 · Balance 106,838 F4: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
F2: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
F4: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 106,838 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · derivative · entry 4 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,838 Underlying: Common Stock · 106,838 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 62,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · derivative · entry 3 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,448 Underlying: Common Shares · 62,448 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 4,849 | $12.01 | $58,236.49 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · nonDerivative · entry 2 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,379 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005118 · wf-form4_164642818108100.xml · nonDerivative · entry 1 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,228 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 20:33 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001628280-21-020527 · wf-form4_163528039067523.xml · derivative · entry 3 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,864 Underlying: Common Stock · 95,000 shares Expires 2027-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 20:33 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 130,000 | $29.75 | $3,867,500.00 |
DisclosureSEC source: 0001628280-21-020527 · wf-form4_163528039067523.xml · nonDerivative · entry 2 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,728 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $30.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 20:33 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 95,000 | $3.20 | $304,000.00 |
DisclosureSEC source: 0001628280-21-020527 · wf-form4_163528039067523.xml · nonDerivative · entry 1 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:53 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 11,136 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001628280-21-019051 · wf-form4_163234399960979.xml · derivative · entry 6 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,864 Underlying: Common Stock · 11,136 shares Expires 2027-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F6 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:53 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001628280-21-019051 · wf-form4_163234399960979.xml · derivative · entry 5 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2022-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F5 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in three equal monthly installments from the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:53 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,364 | $23.66 | $126,912.24 |
DisclosureSEC source: 0001628280-21-019051 · wf-form4_163234399960979.xml · nonDerivative · entry 4 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,728 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.64 to $23.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:53 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 27,136 | $24.05 | $652,620.80 |
DisclosureSEC source: 0001628280-21-019051 · wf-form4_163234399960979.xml · nonDerivative · entry 3 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,092 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.02 to $24.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:53 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 11,136 | $3.20 | $35,635.20 |
DisclosureSEC source: 0001628280-21-019051 · wf-form4_163234399960979.xml · nonDerivative · entry 2 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:53 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 16,000 | $2.63 | $42,080.00 |
DisclosureSEC source: 0001628280-21-019051 · wf-form4_163234399960979.xml · nonDerivative · entry 1 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 22,500 | $21.75 | $489,375.00 |
DisclosureSEC source: 0001628280-21-018595 · wf-form4_163165391729313.xml · nonDerivative · entry 3 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,092 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,000 | $19.76 | $98,800.00 |
DisclosureSEC source: 0001628280-21-018595 · wf-form4_163165391729313.xml · nonDerivative · entry 2 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,592 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 21:12 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,000 | $19.83 | $99,150.00 |
DisclosureSEC source: 0001628280-21-018595 · wf-form4_163165391729313.xml · nonDerivative · entry 1 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,592 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 20:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,000 | $18.30 | $91,500.00 |
DisclosureSEC source: 0001628280-21-018218 · wf-form4_163113139756555.xml · nonDerivative · entry 1 Huizinga Robert Bindert · CIK 0001837648 · EVP of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,592 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $18.30 to $18.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 11, 2021 Filed May 11, 2021 21:22 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001628280-21-009847 · wf-form4_162076816300353.xml · derivative · entry 2 Huizinga Robert Bindert · CIK 0001837648 · Ex Vice President of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2021-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F2 · derivative.exercise_date: The shares subject to the options are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. The expiration date was extended as a result of the blackout period. Read SEC document |
| May 11, 2021 Filed May 11, 2021 21:22 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 40,000 | $3.02 | $120,800.00 |
DisclosureSEC source: 0001628280-21-009847 · wf-form4_162076816300353.xml · nonDerivative · entry 1 Huizinga Robert Bindert · CIK 0001837648 · Ex Vice President of Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.